Myoung H Kim1, Jerel Fields, Jerrel Field. 1. Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, Texas 76107-2699, USA. mkim@hsc.unt.edu
Abstract
BACKGROUND: C/EBP beta is a transcription factor regulating key biological processes including cellular growth and differentiation and its increased expression correlates with tumor invasiveness. Recently, the increased expression of C/EBP beta was reported in proliferative inflammatory atrophy of the prostate, associating with increased COX-2 expression and androgen receptor (AR) downregulation. METHODS: C/EBP beta expression was determined in DU-145, PC-3 and LNCaP cells by immunoblotting. Transient transfection of C/EBP beta expression vectors was performed to investigate translational regulation of its isoform expression. Reporter gene analysis was performed to investigate transcriptional activity of C/EBP beta on metastatic gene expression. RESULTS: We determined that transcriptionally active, full-length C/EBP beta isoforms were dominantly expressed in hormone-independent DU-145 and PC-3 cells, while transcription-repressing truncated isoform was dominant in hormone-dependent LNCaP cells. Our results further showed lack of full-length isoform expression from the transiently transfected C/EBP beta expression vector in LNCaP cells compared to that in PC-3 cells transfected with the same vector, while the expression of truncated isoform was comparable in both cell lines. Interestingly, however, the most upstream initiation site A null mutation restored translation of full-length isoform in LNCaP cells. These results suggest that full-length C/EBP beta isoform expression in LNCaP cells may be suppressed at the upstream initiation sites, likely at site A. Most importantly, C/EBP beta overexpression significantly upregulated promoter activities of IL-8, COX-2, and anti-apoptotic Bfl-1 genes. CONCLUSIONS: Our study demonstrates that C/EBP beta is an important transcription factor upregulating metastatic gene expression and that its isoform expression is differentially regulated at the translational level in prostate cancer cells. (c) 2008 Wiley-Liss, Inc.
BACKGROUND:C/EBP beta is a transcription factor regulating key biological processes including cellular growth and differentiation and its increased expression correlates with tumor invasiveness. Recently, the increased expression of C/EBP beta was reported in proliferative inflammatory atrophy of the prostate, associating with increased COX-2 expression and androgen receptor (AR) downregulation. METHODS:C/EBP betaexpression was determined in DU-145, PC-3 and LNCaP cells by immunoblotting. Transient transfection of C/EBP betaexpression vectors was performed to investigate translational regulation of its isoform expression. Reporter gene analysis was performed to investigate transcriptional activity of C/EBP beta on metastatic gene expression. RESULTS: We determined that transcriptionally active, full-length C/EBP beta isoforms were dominantly expressed in hormone-independent DU-145 and PC-3 cells, while transcription-repressing truncated isoform was dominant in hormone-dependent LNCaP cells. Our results further showed lack of full-length isoform expression from the transiently transfected C/EBP betaexpression vector in LNCaP cells compared to that in PC-3 cells transfected with the same vector, while the expression of truncated isoform was comparable in both cell lines. Interestingly, however, the most upstream initiation site A null mutation restored translation of full-length isoform in LNCaP cells. These results suggest that full-length C/EBP beta isoform expression in LNCaP cells may be suppressed at the upstream initiation sites, likely at site A. Most importantly, C/EBP beta overexpression significantly upregulated promoter activities of IL-8, COX-2, and anti-apoptotic Bfl-1 genes. CONCLUSIONS: Our study demonstrates that C/EBP beta is an important transcription factor upregulating metastatic gene expression and that its isoform expression is differentially regulated at the translational level in prostate cancer cells. (c) 2008 Wiley-Liss, Inc.
Authors: Y Yan; E A Hanse; K Stedman; J M Benson; X H Lowman; S Subramanian; A Kelekar Journal: Cell Death Differ Date: 2016-02-12 Impact factor: 15.828
Authors: Amel Saadi; Nicholas B Shannon; Pierre Lao-Sirieix; Maria O'Donovan; Elaine Walker; Nicholas J Clemons; James S Hardwick; Chunsheng Zhang; Madhumita Das; Vicki Save; Marco Novelli; Frances Balkwill; Rebecca C Fitzgerald Journal: Proc Natl Acad Sci U S A Date: 2010-01-13 Impact factor: 11.205
Authors: Igor V Deyneko; Alexander E Kel; Olga V Kel-Margoulis; Elena V Deineko; Edgar Wingender; Siegfried Weiss Journal: BMC Bioinformatics Date: 2013-08-08 Impact factor: 3.169
Authors: Benjamin Péant; Sophie Gilbert; Cécile Le Page; Alexis Poisson; Emilie L'Ecuyer; Zied Boudhraa; Marc Nicolas Bienz; Nathalie Delvoye; Fred Saad; Anne-Marie Mes-Masson Journal: Oncotarget Date: 2017-02-28